구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 5개 · 임상 갱신 필요 1개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | durvalumab (Imfinzi, MEDI4736) AstraZeneca·PD-L1 750 trials·t½ ~21 days (10 mg/kg q2w historical; flat mg dosing per current label) | ||||
|---|---|---|---|---|---|
Overview Program | Opdivo (nivolumab) | Imfinzi (durvalumab) | Tecentriq (atezolizumab) | Imdelltra (tarlatamab) | Ramucirumab |
Overview Company | Bristol Myers Squibb | AstraZeneca | Roche / Genentech | Amgen | Eli Lilly and Company |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | PD-1 | PD-L1 | PD-L1 | DLL3 × CD3 | Non-Small Cell Lung Cancer |
Overview Indication | Melanoma, NSCLC, RCC, HCC, MSI-H tumors, and others | NSCLC (Stage III consolidation), SCLC, biliary tract, HCC | NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others | Extensive-stage small cell lung cancer after platinum-based chemotherapy | Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | novel approach to enhance antitumor therapy using aPD1 and aCTLA-4 | novel small molecule A 2A R antagonist which inhibits downstream signaling and increases T cell function as well as a novel m | novel agents have been approved in recent years (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln, N-803), | DLL3 is expressed on ~85–95% of SCLC tumors but almost absent from normal tissue, which is rare for a solid-tumor engager target. | novel 5-exo-miRNA panel for predicting response to second-line PTX plus RAM therapy in gastric cancer |
Positioning Known limitation | Loss of MHC-I/antigen presentation, β2M/JAK mutations, TIM-3/LAG-3 upregulation. | escape detection by the immune system | resistance to existing therapies | Neuroendocrine-to-non-neuroendocrine plasticity with DLL3 loss; T-cell exhaustion. | resistance to VEGFR2 blockade |
Positioning Development positioning | — | — | — | Only approved DLL3-directed therapy after the failure of rovalpituzumab tesirine. | — |
MoA Mechanism | Nivolumab is a human IgG4 monoclonal antibody that binds the PD-1 receptor on T cells, blocking interaction with PD-L1 and PD-L2 and releasing PD-1 pathway-mediated inhibition of antitumor immune responses. | Durvalumab inhibits PD-L1 binding to PD-1 and CD80 (B7.1), counteracting tumor immune evasion and enhancing cytotoxic T-lymphocyte activity. | Atezolizumab binds PD-L1 and blocks its interaction with PD-1 and B7.1 (CD80), enabling restoration of antitumor T-cell responses without direct PD-1 engagement on T cells. | Binds DLL3 on SCLC cells and CD3 on T cells, forcing a cytolytic synapse that kills tumor cells regardless of native TCR specificity. | targets vascular endothelial growth factor receptor |
MoA Biomarker | PD-1 with slow dissociation and preferential binding in TME-mimicking low | Unresectable Stage III NSCLC post-cCRT (PACIFIC); PD-L1 in other tumors. | PD-L1 IC/TC scoring in NSCLC and UC; tumor-type-specific thresholds. | DLL3 expression by IHC is not required in the label but tracks with the biology. | biomarkers exist to predict therapeutic response |
PK/PD Half-life | 25 h | ~21 days (10 mg/kg q2w historical; flat mg dosing per current label) | 27 h | ~11 days (Fc-extended) | 14 h |
PK/PD Species | Mouse, Objective response, duration of response, exploratory ctDNA clearance | Mouse, OS and PFS benefit in PACIFIC, pCR rates in neoadjuvant trials | Mouse, Human | Cynomolgus monkey, Cytokine kinetics, T-cell margination, radiographic response | Mouse |
PK/PD Animal (cat.) | Mouse | Mouse, In vitro | Human, Mouse | Human, NHP, In vitro | Mouse |
PK/PD Experiment | PD | PD | PD | pharmacokinetic | Biodistribution |
Toxicology Species | Cynomolgus monkey, Macaque, Mouse | Cynomolgus monkey, Macaque, Mouse | Cynomolgus monkey, Mouse, Human | Mouse | Mouse |
Toxicology Animal (cat.) | NHP | — | — | — | Mouse |
Toxicology Major finding | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Boxed warning for CRS and neurologic toxicity including ICANS. Cytopenia and fatigue are common; step-up dosing with monitoring is mandatory. | Risk factors of docetaxel-induced peripheral edema in non-small cell lung cancer treatment: a multi-institutional cohort study.. Peripheral edema is an adverse event associated with docetaxel (DTX). However, previous studies on DTX-induced peripheral edema have been limited to patients with breast cancer. Therefore, evaluation of symptoms in other cancer types is essential. We aimed to identify th… |
Toxicology CRS | N/A (checkpoint inhibitor) | N/A | N/A | CRS ~51–55%, mostly grade 1–2 | — |
Clinical Safety signal | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Boxed warning for CRS and neurologic toxicity including ICANS. Cytopenia and fatigue are common; step-up dosing with monitoring is mandatory. | Risk factors of docetaxel-induced peripheral edema in non-small cell lung cancer treatment: a multi-institutional cohort study.. Peripheral edema is an adverse event associated with docetaxel (DTX). However, previous studies on DTX-induced peripheral edema have been limited to patients with breast cancer. Therefore, evaluation of symptoms in other cancer types is essential. We aimed to identify th… |
Clinical Selected reported efficacy | ORR 100% | — | — | ORR 57.1% | ORR 37.5% |
Clinical Reported ORR | 100% | 0% | — | 57.1% | 37.5% |
Clinical Reported PFS | — | — | 1.7 | 6.5 | — |
Clinical Reported OS | — | — | 7.6 | NA | — |
Clinical Result source | ClinicalTrials.gov NCT03267498 | ClinicalTrials.gov NCT04372927 | ClinicalTrials.gov NCT04457778 | ClinicalTrials.gov NCT04885998 | ClinicalTrials.gov NCT04499924 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT03267498 | NCT04372927 | NCT04457778 | NCT04885998 | NCT04499924 |
Preclinical Animal (cat.) | — | — | Mouse | Mouse, In vitro | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 5개 · 임상 갱신 필요 1개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | durvalumab (Imfinzi, MEDI4736) AstraZeneca·PD-L1 750 trials·t½ ~21 days (10 mg/kg q2w historical; flat mg dosing per current label) | ||||
|---|---|---|---|---|---|
Overview Program | Opdivo (nivolumab) | Imfinzi (durvalumab) | Tecentriq (atezolizumab) | Imdelltra (tarlatamab) | Ramucirumab |
Overview Company | Bristol Myers Squibb | AstraZeneca | Roche / Genentech | Amgen | Eli Lilly and Company |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | PD-1 | PD-L1 | PD-L1 | DLL3 × CD3 | Non-Small Cell Lung Cancer |
Overview Indication | Melanoma, NSCLC, RCC, HCC, MSI-H tumors, and others | NSCLC (Stage III consolidation), SCLC, biliary tract, HCC | NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others | Extensive-stage small cell lung cancer after platinum-based chemotherapy | Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | novel approach to enhance antitumor therapy using aPD1 and aCTLA-4 | novel small molecule A 2A R antagonist which inhibits downstream signaling and increases T cell function as well as a novel m | novel agents have been approved in recent years (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln, N-803), | DLL3 is expressed on ~85–95% of SCLC tumors but almost absent from normal tissue, which is rare for a solid-tumor engager target. | novel 5-exo-miRNA panel for predicting response to second-line PTX plus RAM therapy in gastric cancer |
Positioning Known limitation | Loss of MHC-I/antigen presentation, β2M/JAK mutations, TIM-3/LAG-3 upregulation. | escape detection by the immune system | resistance to existing therapies | Neuroendocrine-to-non-neuroendocrine plasticity with DLL3 loss; T-cell exhaustion. | resistance to VEGFR2 blockade |
Positioning Development positioning | — | — | — | Only approved DLL3-directed therapy after the failure of rovalpituzumab tesirine. | — |
MoA Mechanism | Nivolumab is a human IgG4 monoclonal antibody that binds the PD-1 receptor on T cells, blocking interaction with PD-L1 and PD-L2 and releasing PD-1 pathway-mediated inhibition of antitumor immune responses. | Durvalumab inhibits PD-L1 binding to PD-1 and CD80 (B7.1), counteracting tumor immune evasion and enhancing cytotoxic T-lymphocyte activity. | Atezolizumab binds PD-L1 and blocks its interaction with PD-1 and B7.1 (CD80), enabling restoration of antitumor T-cell responses without direct PD-1 engagement on T cells. | Binds DLL3 on SCLC cells and CD3 on T cells, forcing a cytolytic synapse that kills tumor cells regardless of native TCR specificity. | targets vascular endothelial growth factor receptor |
MoA Biomarker | PD-1 with slow dissociation and preferential binding in TME-mimicking low | Unresectable Stage III NSCLC post-cCRT (PACIFIC); PD-L1 in other tumors. | PD-L1 IC/TC scoring in NSCLC and UC; tumor-type-specific thresholds. | DLL3 expression by IHC is not required in the label but tracks with the biology. | biomarkers exist to predict therapeutic response |
PK/PD Half-life | 25 h | ~21 days (10 mg/kg q2w historical; flat mg dosing per current label) | 27 h | ~11 days (Fc-extended) | 14 h |
PK/PD Species | Mouse, Objective response, duration of response, exploratory ctDNA clearance | Mouse, OS and PFS benefit in PACIFIC, pCR rates in neoadjuvant trials | Mouse, Human | Cynomolgus monkey, Cytokine kinetics, T-cell margination, radiographic response | Mouse |
PK/PD Animal (cat.) | Mouse | Mouse, In vitro | Human, Mouse | Human, NHP, In vitro | Mouse |
PK/PD Experiment | PD | PD | PD | pharmacokinetic | Biodistribution |
Toxicology Species | Cynomolgus monkey, Macaque, Mouse | Cynomolgus monkey, Macaque, Mouse | Cynomolgus monkey, Mouse, Human | Mouse | Mouse |
Toxicology Animal (cat.) | NHP | — | — | — | Mouse |
Toxicology Major finding | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Boxed warning for CRS and neurologic toxicity including ICANS. Cytopenia and fatigue are common; step-up dosing with monitoring is mandatory. | Risk factors of docetaxel-induced peripheral edema in non-small cell lung cancer treatment: a multi-institutional cohort study.. Peripheral edema is an adverse event associated with docetaxel (DTX). However, previous studies on DTX-induced peripheral edema have been limited to patients with breast cancer. Therefore, evaluation of symptoms in other cancer types is essential. We aimed to identify th… |
Toxicology CRS | N/A (checkpoint inhibitor) | N/A | N/A | CRS ~51–55%, mostly grade 1–2 | — |
Clinical Safety signal | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Boxed warning for CRS and neurologic toxicity including ICANS. Cytopenia and fatigue are common; step-up dosing with monitoring is mandatory. | Risk factors of docetaxel-induced peripheral edema in non-small cell lung cancer treatment: a multi-institutional cohort study.. Peripheral edema is an adverse event associated with docetaxel (DTX). However, previous studies on DTX-induced peripheral edema have been limited to patients with breast cancer. Therefore, evaluation of symptoms in other cancer types is essential. We aimed to identify th… |
Clinical Selected reported efficacy | ORR 100% | — | — | ORR 57.1% | ORR 37.5% |
Clinical Reported ORR | 100% | 0% | — | 57.1% | 37.5% |
Clinical Reported PFS | — | — | 1.7 | 6.5 | — |
Clinical Reported OS | — | — | 7.6 | NA | — |
Clinical Result source | ClinicalTrials.gov NCT03267498 | ClinicalTrials.gov NCT04372927 | ClinicalTrials.gov NCT04457778 | ClinicalTrials.gov NCT04885998 | ClinicalTrials.gov NCT04499924 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT03267498 | NCT04372927 | NCT04457778 | NCT04885998 | NCT04499924 |
Preclinical Animal (cat.) | — | — | Mouse | Mouse, In vitro | — |
추천 비교
추천 비교